Basal sFAS/sFASL ratio and FAS polymorphisms, as a prognostic marker, in advanced colorectal carcinoma patients (ACRC), treated with oxaliplatin-based chemotherapy.

被引：0
|
作者：
Gascon, P
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：278S / 278S
页数：1
相关论文
共 50 条
  • [1] FAS/FAS ligand ratio:: A marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer
    Nadal, C
    Maurel, J
    Gallego, R
    Castells, A
    Longarón, R
    Marmol, M
    Sanz, S
    Molina, R
    Martin-Richard, M
    Gascón, P
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4770 - 4774
  • [2] Advanced colorectal cancer (ACRC) in elderly patients: Evaluation of three different oxaliplatin-based chemotherapy regimens
    Pinto, Carmine
    Di Fabio, Francesca
    Gentile, Anna Lisa
    Mini, Enrico
    Giaquinta, Stefania
    Llimpe, Fabiola Lorena Rojas
    Mutri, Vita
    Piana, Edera
    Mazzei, Teresita
    Martoni, Andrea
    ANNALS OF ONCOLOGY, 2005, 16 : 47 - 47
  • [3] Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Bahrami, Afsane
    Amerizadeh, Forouzan
    Hassanian, Seyed Mahdi
    ShahidSales, Soodabeh
    Khazaei, Majid
    Maftouh, Mina
    Ghayour-Mobarhan, Majid
    Ferns, Gordon A.
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (03) : 2193 - 2201
  • [4] Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
    de Gramont Lesparre, A. H.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A. K.
    Afchain, P.
    Louvet, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] DEFINITION OF OXALIPLATIN SENSITIVITY IN PATIENTS WITH ADVANCED COLORECTAL CANCER PREVIOUSLY TREATED WITH OXALIPLATIN-BASED THERAPY
    de Gramont, A.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A.
    Afchain, P.
    Louvet, C.
    ANNALS OF ONCOLOGY, 2009, 20 : 13 - 13
  • [6] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    L Paré-Brunet
    A Sebio
    J Salazar
    A Berenguer-Llergo
    E Río
    A Barnadas
    M Baiget
    D Páez
    The Pharmacogenomics Journal, 2015, 15 : 397 - 404
  • [7] Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy
    Pare-Brunet, L.
    Sebio, A.
    Salazar, J.
    Berenguer-Llergo, A.
    Rio, E.
    Barnadas, A.
    Baiget, M.
    Paez, D.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (05): : 397 - 404
  • [8] Second-line bevacizumab plus FOLFOX in patients with metastatic colorectal cancer previously treated with adjuvant oxaliplatin-based chemotherapy.
    Chun, Sang Hoon
    Kim, Jung Hoon
    Kwag, Seung-Jin
    Kang, Myoung Hee
    Park, Ji-Ho
    Lee, Gyeong-Won
    Kang, Jung Hun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 157 - 157
  • [9] Identification of an immunological prognostic factor for metastatic colorectal cancer patients treated with first-line oxaliplatin-based chemotherapy
    Tada, K.
    Shoji, H.
    Kitano, S.
    Nishimura, T.
    Shimada, Y.
    Nagashima, K.
    Ito, A.
    Honma, Y.
    Iwasa, S.
    Okita, N.
    Takashima, A.
    Kato, K.
    Yamada, Y.
    Katayama, N.
    Boku, N.
    Heike, Y.
    Hamaguchi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S80 - S80
  • [10] Elevated Neutrophil to Lymphocyte Ratio Predicts Poor Prognosis in Advanced Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy
    Kaneko, Manabu
    Nozawa, Hiroaki
    Sasaki, Kazuhito
    Hongo, Kumiko
    Hiyoshi, Masaya
    Tada, Noriko
    Murono, Koji
    Nirei, Takako
    Kawai, Kazushige
    Sunami, Eiji
    Tsuno, Nelson H.
    Kitayama, Joji
    ONCOLOGY, 2012, 82 (05) : 261 - 268
12345